Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Giovanni Martinelli et al.|Journal of Clinical Oncology|2015Cited by 63
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Eva Kimby, Stéphanie Rondeau et al.|Blood|2019Cited by 61
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Georg Stüssi, Kornelius Arn et al.|Blood Advances|2020Cited by 31
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A. Moccia, Emanuele Zucca, Christian Taverna et al.|Blood Advances|2020Cited by 25
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Giovanni Martinelli et al.|Blood|2014Cited by 18